Trial Profile
ONO-4538 Phase III Study A Multicenter, Double-Blind, Randomized Study in Patients With Unresectable Advanced or Recurrent Gastric Cancer
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 25 Apr 2022
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- Acronyms ATTRACTION-2
- Sponsors Ono Pharmaceutical
- 09 Apr 2022 Results assessing predictive values of blood neutrophil-lymphocyte ratio (NLR), serum Na, PD-L1 expression, MSI status, tumor EBV infection, and tumor mutation burden (TMB), published in the BMC Cancer.
- 19 Mar 2021 Status changed from active, no longer recruiting to completed.
- 25 Jan 2020 Results of three-years updated data (as of Feb 2019) presented at the 2020 Gastrointestinal Cancers Symposium.